Full Press Release Details
| Dr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 | ||
| Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com |
| June 15, 2017 | ||
| Surveillance Department | National Stock Exchange of India Ltd. | |
| BSE Limited | Exchange Plaza | |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | |
| Mumbai 400 001 | Mumbai 400 051 | |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ | |
| 22722037 / 22722039 | 26598238 | |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
email dated June 14, 2017
Sub: Clarification on news item appearing in Business Standard dated June 14, 2017 captioned Dr
Reddy s recalls 3.25L cartons Cipla-made acne drug from US.
This is with reference to your email dated June 14, 2017, seeking
clarification on the above subject.
In this regard, we would like to state that the Company has voluntarily recalled Cipla-made Zenatane (isotretinoin)
capsules used for treatment of severe acne, from the US markets. This recall is in conformance with our quality assurance norms.
The Company believes
that recall of products by the Company is a usual activity in the normal course of pharmaceutical industries business operations. Further, the overall impact on the Company s financials of this recall is not likely to be significant.
We regularly inform all concerned on material events and presently do not have any other information which is material to the Company s operations or
consolidated results.
This is for your information.
| /s/ Sandeep Poddar |
| Sandeep Poddar |
| Company Secretary |
CC: New York Stock Exchange Inc.(Stock Code: RDY)